Renewal of Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CSCPDPC - CCs)

May 2023 Council

Lead Division/Office

DDN

Point(s) of Contact

Aynur Unalp-Arida; Jose Serrano

Executive Summary

Pancreatic disease leads to significant morbidity, mortality, and health care utilization in the United States. Research progress in diseases of the exocrine pancreas [chronic pancreatitis (CP), pancreatogenic diabetes mellitus, and pancreatic cancer] have been hampered by multiple limitations. To address research gaps in CP and its sequelae, the NIDDK and the NCI, funded the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer in September 2015.The CPDPC have initiated four major studies: the Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies, the International Study Group of Pediatric Pancreatitis: In Search for a Cure, a New Onset Diabetes Cohort, and the diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis. Continuation of the consortium will accomplish several goals: a) to define and characterize the risks and natural histories of pancreatic diseases (including their progression) and their relationship to diabetes; b) to develop enhanced methods and biomarkers for prediction, early diagnosis, and monitoring effects of interventions to prevent, delay and/or attenuate the pancreatic diseases; and c) to proposed clinical trial designs for effective testing of therapeutic interventions.